Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum is provided. The commercial attractiveness is unknown.
Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Non-exclusive discount agreements for Naltrexone (ATC N07BB04) under §130a Abs. 8 SGB V
- Contract duration: July 1, 2025 to June 30, 2027
Show full summary
This is an open-house model (non-procurement) for non-exclusive discount agreements on Naltrexone (ATC N07BB04) with AOK Bayern. Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and signed contract documents. The contract runs from July 1, 2025 to June 30, 2027. No estimated value is provided. The notice is published under procurement forms but is explicitly stated not to be a procurement procedure.
Risks
No estimated value or framework maximum is provided. The commercial attractiveness is unknown.
Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Eligibility: only pharmaceutical companies may participate
Administrative
- Submission of signed contract, annex listing covered medicines, and signed declaration of reliability
- Documents can be submitted in paper (two originals) or electronically with qualified electronic signature
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04
Non-exclusive discount agreements for the active substance Naltrexone (ATC N07BB04). Eligible pharmaceutical companies can join at any time until May 5, 2027. Contracts are identical and not negotiable. Early termination possible with one-month notice. The open-house agreements automatically cease if a nationwide or regional discount contract is concluded via a formal procurement procedure.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 317360-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum is provided. The commercial attractiveness is unknown.
Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications